Intelligence · Clinical Pipeline

Sanofi-Aventis U.S Pipeline

All ClinicalTrials.gov programs at Sanofi-Aventis U.S — phase, modality, and trial IDs.

Programs: 49

Quick answer

Sanofi-Aventis U.S has 49 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

-, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

Sanofi-aventis Healthcare Pty Ltd

Nervous system diseases

phase 3 small molecule active

1 trial
-, TACROLIMUS , Amlitelimab, PIMECROLIMUS , Placebo, Amlitelimab

Sanofi-aventis Healthcare Pty Ltd

Dermatitis atopic

phase 3 small molecule active

1 trial
A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

Sanofi-aventis Healthcare Pty Ltd

Immune system diseases

phase 3 other active

1 trial
AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -

Sanofi-aventis Healthcare Pty Ltd

Nervous system diseases

phase 3 small molecule active

1 trial
AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab

Sanofi-aventis Healthcare Pty Ltd

multiple sclerosis

phase 3 small molecule active

1 trial
Amlitelimab, Amlitelimab, -, -, -, Amlitelimab

Sanofi-aventis Healthcare Pty Ltd

Dermatitis atopic

phase 3 small molecule active

1 trial
Amlitelimab, Placebo, -, TACROLIMUS , PIMECROLIMUS , Amlitelimab

Sanofi-aventis Healthcare Pty Ltd

Dermatitis atopic

phase 3 small molecule active

1 trial
Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

Sanofi-aventis Healthcare Pty Ltd

atopic dermatitis

phase 3 small molecule active

1 trial
Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection

Sanofi-aventis Healthcare Pty Ltd

Thrombotic Thrombocytopenic Purpura

phase 3 small molecule active

1 trial
Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671

Sanofi-aventis Healthcare Pty Ltd

Gaucher's disease type III

phase 3 small molecule active

1 trial
Dupilumab, Matched placebo for test product

Sanofi-aventis Healthcare Pty Ltd

Neurodermatitis

phase 3 small molecule active

1 trial
Dupilumab, Matched placebo for test product

Sanofi-aventis Healthcare Pty Ltd

Neurodermatitis

phase 3 small molecule active

1 trial
Duvakitug, Matched placebo for test product

Sanofi-aventis Healthcare Pty Ltd

Immune system diseases

phase 3 small molecule active

1 trial
Duvakitug, matched placebo for test product

Sanofi-aventis Healthcare Pty Ltd

Immune system diseases

phase 3 small molecule active

1 trial
FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

Sanofi-aventis Healthcare Pty Ltd

Respiratory tract diseases - Wheezing, Asthma

phase 3 small molecule active

1 trial
Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.

Sanofi-aventis Healthcare Pty Ltd

Fabry’s disease

phase 3 small molecule active

1 trial
Frexalimab

Sanofi-aventis Healthcare Pty Ltd

Multiple Sclerosis

phase 3 small molecule active

1 trial
Imnovid 3 mg hard capsules, Isatuximab, Dexamethason 4 mg JENAPHARM®, JAMP Pomalidomide, JAMP Pomalidomide, Isatuximab, Imnovid 4 mg hard capsules, JAMP Pomalidomide, MONTELUKAST , Pomalidomide Adalvo 4 mg hard capsules, JAMP Pomalidomide, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Imnovid 1 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, DEXAMETHASONE, Imnovid 1 mg hard capsules, Isatuximab, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Dexamethason

Sanofi-aventis Healthcare Pty Ltd

Cancer - Plasma cell myeloma recurrent

phase 3 small molecule active

1 trial
Itepekimab, Matched Placebo for test product

Sanofi-aventis Healthcare Pty Ltd

Chronic Obstructive Pulmonary Disease

phase 3 small molecule active

1 trial
Itepekimab, Matched placebo for test product

Sanofi-aventis Healthcare Pty Ltd

Chronic rhinosinusitis with nasal polyps

phase 3 small molecule active

1 trial
Itepekimab, Matched placebo for test product

Sanofi-aventis Healthcare Pty Ltd

Chronic Obstructive Pulmonary Disease

phase 3 small molecule active

1 trial
LORATADINE , FEXOFENADINE , Dupilumab, Matched placebo to test

Sanofi-aventis Healthcare Pty Ltd

Pruritus

phase 3 small molecule active

1 trial
Live Attenuated Respiratory Syncytial Virus (RSV) ∆NS2/∆1313/I1314L vaccine, Matched

Sanofi-aventis Healthcare Pty Ltd

Virus diseases

phase 3 small molecule active

1 trial
Matched placebo for product, Frexalimab

Sanofi-aventis Healthcare Pty Ltd

Multiple sclerosis

phase 3 small molecule active

1 trial
Matched placebo for test product, Duvakitug

Sanofi-aventis Healthcare Pty Ltd

Immune system disseases

phase 3 small molecule active

1 trial
Matched placebo for test product, Itepekimab

Sanofi-aventis Healthcare Pty Ltd

Chronic rhinosinusitis with nasal polyps

phase 3 small molecule active

1 trial
Matched placebo for test product, Itepekimab

Sanofi-aventis Healthcare Pty Ltd

Chronic rhinosinusitis with nasal polyps

phase 3 small molecule active

1 trial
Matched placebo for test product, Itepekimab

Sanofi-aventis Healthcare Pty Ltd

Chronic Obstructive Pulmonary Disease

phase 3 small molecule active

1 trial
Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, avalglucosidase alfa, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion

Sanofi-aventis Healthcare Pty Ltd

Glycogen storage disease type II

phase 3 small molecule active

1 trial
PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS

Sanofi-aventis Healthcare Pty Ltd

Dermatitis atopic

phase 3 small molecule active

1 trial
PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS

Sanofi-aventis Healthcare Pty Ltd

Dermatitis atopic

phase 3 small molecule active

1 trial
PREVNAR 20 ®, Pneumococcal Conjugate Vaccine (PCV)

Sanofi-aventis Healthcare Pty Ltd

Pneumococcal immunisation

phase 3 small molecule active

1 trial
Placebo 15mg Tablets, Placebo 6mg tablets, venglustat GZ402671 - SAR402671, venglustat GZ402671 - SAR402671

Sanofi-aventis Healthcare Pty Ltd

Fabry Disease

phase 3 small molecule active

1 trial
Prograft 5 mg capsules, hard, Prograf 0,5 mg Hartkapseln, Prograf 1 mg Hartkapseln, Frexalimab, Prograft 0,5 mg capsules, hard, Prograft 1 mg capsules, hard, Prograf 5 mg Hartkapseln

Sanofi-aventis Healthcare Pty Ltd

Kidney transplant rejection

phase 3 small molecule active

1 trial
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

Sanofi-aventis Healthcare Pty Ltd

multiple sclerosis

phase 3 other active

1 trial
Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

Sanofi-aventis Healthcare Pty Ltd

Non-small cell lung cancer metastatic

phase 3 other active

1 trial
Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Revlimid 10 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 15 mg hard capsules, Isa

Sanofi-aventis Healthcare Pty Ltd

Plasma cell myeloma

phase 3 small molecule active

1 trial
Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules,

Sanofi-aventis Healthcare Pty Ltd

Cancer

phase 3 small molecule active

1 trial
Rilzabrutinib

Sanofi-aventis Healthcare Pty Ltd

immune thrombocytopenia (ITP)

phase 3 small molecule active

1 trial
SAR439774, SAR439774

Sanofi-aventis Healthcare Pty Ltd

Hemophilia

phase 3 small molecule active

1 trial
Sar444671 placebo - matched placebo for test, Rilzabrutinib

Sanofi-aventis Healthcare Pty Ltd

Autoimmune haemolytic anaemia

phase 3 small molecule active

1 trial
Sar444671 placebo - matched placebo for test, Rilzabrutinib

Sanofi-aventis Healthcare Pty Ltd

Blood and lymphatic diseases

phase 3 small molecule active

1 trial
Teplizumab, Matched placebo for test product

Sanofi-aventis Healthcare Pty Ltd

Nutritional and metabolic diseases

phase 3 small molecule active

1 trial
Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)

Sanofi-aventis Healthcare Pty Ltd

Pneumococcal Immunization

phase 3 small molecule active

1 trial
matched placebo for test product, Duvakitug

Sanofi-aventis Healthcare Pty Ltd

Immune system diseases

phase 3 small molecule active

1 trial
riliprubart

Sanofi-aventis Healthcare Pty Ltd

Immune system diseases.

phase 3 small molecule active

1 trial
riliprubart placebo, solution for injection in prefilled pen (PFP), riliprubart placebo, solution for injection in vial, riliprubart, riliprubart

Sanofi-aventis Healthcare Pty Ltd

Polyneuropathy, Inflammatory Demyelinating, Chronic

phase 3 small molecule active

1 trial
riliprubart, -, riliprubart placebo solution for injection in prefilled pen, placebo matching IVIg, riliprubart, riliprubart placebo solution for injection in vial, -

Sanofi-aventis Healthcare Pty Ltd

Chronic Inflammatory Demyelinating Polyneuropathy

phase 3 small molecule active

1 trial

Frequently asked questions

How many pipeline programs does Sanofi-Aventis U.S have?

49 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Quick answer

-, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

-, TACROLIMUS , Amlitelimab, PIMECROLIMUS , Placebo, Amlitelimab

A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -

AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab

Amlitelimab, Amlitelimab, -, -, -, Amlitelimab

Amlitelimab, Placebo, -, TACROLIMUS , PIMECROLIMUS , Amlitelimab

Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection

Dupilumab, Matched placebo for test product

Dupilumab, Matched placebo for test product

Duvakitug, Matched placebo for test product

Duvakitug, matched placebo for test product

FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.

Frexalimab

Itepekimab, Matched Placebo for test product

Itepekimab, Matched placebo for test product

Itepekimab, Matched placebo for test product

LORATADINE , FEXOFENADINE , Dupilumab, Matched placebo to test

Live Attenuated Respiratory Syncytial Virus (RSV) ∆NS2/∆1313/I1314L vaccine, Matched

Matched placebo for product, Frexalimab

Matched placebo for test product, Duvakitug

Matched placebo for test product, Itepekimab

Matched placebo for test product, Itepekimab

Matched placebo for test product, Itepekimab

Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, avalglucosidase alfa, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion

PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS

PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS

PREVNAR 20 ®, Pneumococcal Conjugate Vaccine (PCV)

Placebo 15mg Tablets, Placebo 6mg tablets, venglustat GZ402671 - SAR402671, venglustat GZ402671 - SAR402671

Prograft 5 mg capsules, hard, Prograf 0,5 mg Hartkapseln, Prograf 1 mg Hartkapseln, Frexalimab, Prograft 0,5 mg capsules, hard, Prograft 1 mg capsules, hard, Prograf 5 mg Hartkapseln

Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

Rilzabrutinib

SAR439774, SAR439774

Sar444671 placebo - matched placebo for test, Rilzabrutinib

Sar444671 placebo - matched placebo for test, Rilzabrutinib

Teplizumab, Matched placebo for test product

Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)

matched placebo for test product, Duvakitug

riliprubart

riliprubart placebo, solution for injection in prefilled pen (PFP), riliprubart placebo, solution for injection in vial, riliprubart, riliprubart

riliprubart, -, riliprubart placebo solution for injection in prefilled pen, placebo matching IVIg, riliprubart, riliprubart placebo solution for injection in vial, -

Frequently asked questions

Stay Ahead in Pharma